2023-509399-40-00CompletedPhase 1
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Apr 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 28 Nov 2023
- Start date
- 9 May 2024
- Lead sponsor
- Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.
- EU CT number
- 2023-509399-40-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda Ospedaliero Universitaria Pisana | Pisa | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.